Columnist Dan Mack discusses how the moment you slip into an old and tired sales pitch, you’ve fumbled the opportunity.
Sufficiently similar: What the FDA approval of the first interchangeable biosimilar product means for pharmacists
The approval means that pharmacists will be allowed to switch out Lantus (insulin glargine) for the Semglee (insulin glargine-yfgn) biosimilar without the required approval from the prescribing physician.
The program can provide access to lifesaving treatments, and allowing pharmacists to prescribe and dispense will make it more effective and accessible for millions of Americans.
Pharmacists have a golden opportunity to promote medication adherence — improving patient outcomes and protecting revenue.
Jason Ausili, chief clinical officer of FDS Amplicare, discusses the challenges pharmacies are facing in the wake of the 21st Century Cures Act.